RESEARCH ARTICLE

Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study

Ryu Matsuo1,2, Tetsuro Ago1, Jun Hata3, Yoshinobu Wakisaka1,3, Junya Kuroda¹, Takahiro Kuwashiro1,4, Takanari Kitazono1,3, Masahiro Kamouchi2,3*, on behalf of the Fukuoka Stroke Registry Investigators¶

1 Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2 Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 3 Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 4 Department of Cerebrovascular Medicine and Neurology, Cerebrovascular Center and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

¶ Membership of the Fukuoka Stroke Registry Investigators is listed in the Acknowledgments.
* kamouchi@hcam.med.kyushu-u.ac.jp

Abstract

Background and Purpose

Although plasma C-reactive protein (CRP) is elevated in response to inflammation caused by brain infarction, the association of CRP with clinical outcomes after acute ischemic stroke remains uncertain. This study examined whether plasma high-sensitivity CRP (hsCRP) levels at onset were associated with clinical outcomes after acute ischemic stroke independent of conventional risk factors and acute infections after stroke.

Methods

We prospectively included 3653 patients with first-ever ischemic stroke who had been functionally independent and were hospitalized within 24 h of onset. Plasma hsCRP levels were measured on admission and categorized into quartiles. The association between hsCRP levels and clinical outcomes, including neurological improvement, neurological deterioration, and poor functional outcome (modified Rankin scale \(\geq 3\) at 3 months), were investigated using a logistic regression analysis.

Results

Higher hsCRP levels were significantly associated with unfavorable outcomes after adjusting for age, sex, baseline National Institutes of Health Stroke Scale score, stroke subtype, conventional risk factors, intravenous thrombolysis and endovascular therapy, and acute infections during hospitalization (multivariate-adjusted odds ratios [95% confidence interval] in the highest quartile versus the lowest quartile as a reference: 0.80 [0.65–0.97] for neurological improvement, 1.72 [1.26–2.34] for neurological deterioration, and 2.03 [1.55–2.67] for poor functional outcome (modified Rankin scale \(\geq 3\) at 3 months)).
for a poor functional outcome). These associations were unchanged after excluding patients with infectious diseases occurring during hospitalization, or those with stroke recurrence or death. These trends were similar irrespective of stroke subtypes or baseline stroke severity, but more marked in patients aged <70 years (P_{heterogeneity} = 0.001).

**Conclusions**

High plasma hsCRP is independently associated with unfavorable clinical outcomes after acute ischemic stroke.

**Introduction**

Inflammation plays a key role in the pathogenesis of cerebrovascular diseases via mechanisms including the development of atherosclerosis, plaque instability, and triggering of plaque rupture [1]. Among peripheral blood marker of inflammation, C-reactive protein (CRP), an acute-phase protein, is the most extensively used and established marker [2]. Previous studies suggested that elevation of serum or plasma high-sensitivity CRP (hsCRP) is a strong risk factor for future vascular events, including stroke, in the general population [3–9]. In stroke patients, higher CRP levels in the blood were also shown to be an independent risk factor of future vascular events [9,10–14] or mortality [10,11,13,15–17].

During the acute stage of ischemic stroke, CRP in the blood rises in response to inflammation caused by ischemic brain damage [1,10]. Therefore, plasma CRP levels are elevated owing to underlying vascular lesions as well as inflammation caused by brain infarction in patients with acute ischemic stroke. In a middle cerebral artery occlusion model of adult rats, administration of human CRP resulted in significantly larger cerebral infarcts than control subjects [18]. Further, administration of a specific small-molecule inhibitor of CRP to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP [19]. These findings indicate that CRP itself may worsen ischemic damage. In patients with acute stroke, some studies showed that CRP was related to post-stroke functional outcome [20–22], whereas other groups reported that the association disappeared after adjusting for confounders [16,23,24]. Thus, the association between CRP in the blood and clinical outcomes remains inconclusive in patients with acute ischemic stroke.

To determine whether CRP in the blood is independently associated with short-term outcomes after stroke, we prospectively enrolled patients with first-ever acute ischemic stroke within 24 h of onset and measured plasma CRP on admission using a uniform method. A high-sensitivity test for CRP was used to evaluate accurate levels of CRP, even at low levels. The aim of this study was to elucidate whether plasma hsCRP levels within 24 h of onset were associated with neurological and functional outcomes after acute ischemic stroke independent of conventional risk factors and acute infections.

**Methods**

**Study subjects**

We conducted an hsCRP sub-study of the Fukuoka Stroke Registry (FSR). FSR is a multicenter hospital-based registry, in which acute stroke patients within 7 days of onset were enrolled (UMIN Clinical Trial Registry 000000800) [25,26]. Kyushu University Hospital and six
stroke centers (National Hospital Organization Kyushu Medical Center, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka Red Cross Hospital, St. Mary’s Hospital, Steel Memorial Yawata Hospital, and Japan Labor Health and Welfare Organization Kyushu Rosai Hospital) in Fukuoka, Japan, participate in this registry. The institutional review board of all hospitals approved the study protocols. Written informed consent was obtained from patients or their family members. Standardized instruments were used to collect demographic characteristics, co-morbidities, laboratory data, and medical histories of the patients.

Stroke was defined as a sudden onset of focal neurological deficits persisting for more than 24 h, and was classified into ischemic stroke, brain hemorrhage, subarachnoid hemorrhage, or other types of stroke using brain imaging data (computed tomography and/or magnetic resonance imaging). In this study, ischemic stroke was further classified into four subtypes according to TOAST criteria [27]: cardioembolic, large artery atherosclerosis, small vessel occlusion, and others.

During the study period from June 2007 to May 2014, 9199 Japanese patients were prospectively registered in the FSR database, of which 4867 patients were diagnosed as having ischemic stroke and hospitalized within 24 h of onset. Patients with impaired activities of daily living before stroke onset or no data on admission hsCRP values were further excluded, and 3653 patients were finally included in the analysis of neurological improvement or deterioration. For analysis of the functional outcome at 3 months after the stroke, 50 patients who could not be followed at 3 months after onset were excluded (S1 Fig).

Clinical assessment

Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg in the chronic stage, or as a previous history of treatment with antihypertensive drugs. Dyslipidemia was defined as a low-density lipoprotein-cholesterol level ≥3.62 mmol/L, high-density lipoprotein-cholesterol level ≤1.03 mmol/L, triglyceride level ≥1.69 mmol/L, or a previous history of treatment with a lipid-lowering drug. Diabetes mellitus was determined by either the diagnostic criteria of the Japan Diabetes Society [28] in the chronic stage or based on a medical history of diabetes. Atrial fibrillation was diagnosed based on electrocardiographic findings on admission or during hospitalization, or a previous history of atrial fibrillation. Smoking was defined as current or former cigarette smoking, and alcohol intake was defined as habitual consumption of alcohol beverages before onset of stroke. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m², in which eGFR was determined using the equation proposed by the Japanese Society of Nephrology as follows: eGFR (mL/min per 1.73 m²) = 194 × (serum creatinine [mg/dL])¹.094 × age [year]²⁰.287 × 0.739 (if female) [29]. Body mass index was measured at admission.

Intravenous thrombolysis was performed using recombinant tissue plasminogen activator. Endovascular therapy included intra-arterial thrombolysis, endovascular thrombectomy, thromboaspiration, and angioplasty. Acute infection was defined as a complication of infectious disease including respiratory tract infection, urinary tract infection, sepsis, and other infections during hospitalization. Neurological severity was scaled by the National Institutes of Health Stroke Scale (NIHSS) score. NIHSS score was assessed on admission and at discharge. Functional outcome was assessed by the modified Rankin Scale (mRS). During hospitalization, the NIHSS and mRS were assessed by trained stroke neurologists. The mRS at the 3-month time point was evaluated by trained and certified research nurses through telephone assessment on the basis of a standardized structured questionnaire that was validated in a previous study to minimize the inter-rater variability [30].
Measurement of plasma CRP

To measure plasma hsCRP levels, venous blood samples were collected from patients on the first admission day within 24 h after symptom onset, and were subsequently frozen and transferred to a single laboratory (SRL, Inc., Tokyo, Japan). Plasma hsCRP levels were measured with latex-enhanced nephelometry. Patients were classified into four groups according to the quartiles of values of hsCRP on admission.

Study outcomes

Neurological improvement was defined as a ≥4-point decrease in the NIHSS score during hospitalization or 0 point at discharge [31]. Neurological deterioration was defined as a ≥2-point increase in the NIHSS score during hospitalization [32]. A poor functional outcome was defined as disability (mRS 3–5) or death (mRS 6). Mortality was defined as all causes of death.

Statistical analysis

Baseline characteristics according to the plasma hsCRP quartiles were compared by analysis of variance, the Wilcoxon rank sum test, and logistic regression analysis as appropriate. Logistic regression analysis was also used to estimate multivariable-adjusted odds ratios and 95% confidence intervals for study outcomes. Multivariable model included age, sex, baseline NIHSS score as a continuous variable, stroke subtypes, hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections [26]. P for heterogeneity was calculated by adding the interaction term of hsCRP quartile × subgroup variable in the model. Statistical analyses were performed using Stata 13 (StataCorp LP, College Station, TX, USA). Probability values of <0.05 were considered statistically significant.

Results

Plasma hsCRP levels on admission and background characteristics

The mean age of the study subjects was 70.8±12.2 years, and 1330 patients (36.4%) were women. The median of plasma hsCRP levels on admission was 1.23 mg/L (interquartile range, 0.50–4.69 mg/L).

Table 1 shows the clinical characteristics of patients according to the hsCRP quartiles. With the elevation of plasma hsCRP level, the age and the frequencies of hypertension, diabetes mellitus, atrial fibrillation, and chronic kidney disease increased, while prevalence of dyslipidemia and drinking decreased. The proportion of cardioembolism was higher as the plasma hsCRP level increased. The admission NIHSS score and the frequency of intravenous thrombolytic therapy and endovascular therapy were increased with an increase in plasma hsCRP values. During hospitalization, 500 patients developed infectious diseases (296 respiratory tract infections, 161 urinary tract infections, 28 sepsis, and 112 other infections). Acute infections were more prevalent in patients with higher levels of plasma hsCRP.

Association between plasma hsCRP levels on admission and clinical outcomes

The odds ratio for neurological improvement decreased as the level of plasma hsCRP increased after adjustment for age, sex, baseline neurological severity, and stroke subtypes (Table 2). Further adjustment for conventional risk factors and acute infections did not alter the results.
Similarly, higher levels of plasma hsCRP were significantly associated with an increased risk of neurological deterioration even after adjusting for multiple confounders (Table 3). The plasma hsCRP levels showed a significant association with poor functional outcome at discharge and at 3 months (Table 4).

Table 1. Characteristics of patients.

|                        | Q1, n = 910 (hsCRP <0.50) | Q2, n = 936 (0.50< hsCRP <1.25) | Q3, n = 898 (1.25< hsCRP <4.70) | Q4, n = 909 (hsCRP >4.70) | P for trend |
|------------------------|---------------------------|---------------------------------|---------------------------------|---------------------------|-------------|
| Age, y, mean±SD        | 68.6±13.3                 | 69.7±12.0                       | 71.3±11.0                       | 73.7±11.9                 | <0.001      |
| Female, n (%)          | 347 (38.1)                | 331 (35.4)                      | 321 (35.8)                      | 331 (36.4)                | 0.51        |
| Risk factors, n (%)    |                           |                                 |                                 |                           |             |
| Hypertension           | 651 (71.5)                | 735 (78.5)                      | 736 (82.0)                      | 754 (83.0)                | <0.001      |
| Dyslipidemia           | 440 (48.4)                | 504 (53.9)                      | 480 (53.5)                      | 392 (43.1)                | 0.03        |
| Diabetes mellitus      | 247 (27.1)                | 265 (28.3)                      | 294 (32.9)                      | 270 (30.2)                | 0.04        |
| Atrial fibrillation    | 179 (19.7)                | 224 (24.0)                      | 261 (29.1)                      | 352 (38.8)                | <0.001      |
| Smoking                | 482 (53.0)                | 528 (56.5)                      | 509 (56.8)                      | 487 (53.9)                | 0.67        |
| Drinking               | 394 (43.3)                | 383 (41.0)                      | 353 (39.3)                      | 316 (34.9)                | <0.001      |
| Chronic kidney diseases, n (%) | 236 (25.9) | 282 (30.2) | 303 (33.8) | 385 (42.4) | <0.001 |
| Body mass index, kg/m², mean±SD | 22.5±3.3 | 23.6±3.4 | 23.5±3.8 | 22.9±3.9 | 0.15 |
| Stroke subtype, n (%)  |                           |                                 |                                 |                           |             |
| Cardioembolism         | 188 (20.7)                | 217 (23.2)                      | 249 (27.7)                      | 343 (37.7)                | <0.001      |
| Large artery atherosclerosis | 109 (12.0) | 149 (15.9) | 172 (19.2) | 160 (17.6) |             |
| Small vessel occlusion | 354 (38.9)                | 335 (35.8)                      | 254 (28.3)                      | 168 (18.5)                |             |
| Others                 | 259 (28.5)                | 235 (25.1)                      | 223 (24.8)                      | 238 (26.2)                |             |
| NIHSS score on admission, median (IQR) | 3 (1–5) | 3 (2–5) | 4 (2–8) | 6 (3–13) | <0.001 |
| Thrombolytic and endovascular therapy, n (%) |                           |                                 |                                 |                           |             |
| Intravenous thrombolysis | 110 (12.1) | 116 (12.4) | 114 (12.7) | 146 (16.1) | 0.02 |
| Endovascular therapy   | 12 (1.3)                  | 16 (1.7)                        | 12 (1.3)                        | 31 (3.4)                  | 0.004       |
| Acute infections, n (%) | 63 (6.9)                  | 89 (9.5)                        | 112 (12.5)                      | 236 (26.0)                | <0.001      |

NIHSS: National Institutes of Health Stroke Scale, IQR: interquartile range. Q1–Q4 indicate four groups according to the quartile of hsCRP values (mg/L).

doi:10.1371/journal.pone.0156790.t001

Table 2. Plasma hsCRP levels and neurological improvement during hospitalization.

|                        | Age- and sex-adjusted | Multivariable-adjusted (model 1) | Multivariable-adjusted (model 2) |
|------------------------|-----------------------|----------------------------------|----------------------------------|
|                        | Events (%) OR (95% CI) | P OR (95% CI) | P OR (95% CI) | P |
| Q1, n = 910 (hsCRP <0.50) | 498 (54.7) 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2, n = 936 (0.50< hsCRP <1.25) | 467 (49.9) 0.83 (0.69–1.00) | 0.047 | 0.83 (0.69–1.00) | 0.06 |
| Q3, n = 898 (1.25< hsCRP <4.70) | 445 (49.6) 0.83 (0.69–1.00) | 0.047 | 0.78 (0.65–0.95) | 0.01 |
| Q4, n = 909 (hsCRP >4.70) | 444 (48.8) 0.82 (0.68–0.99) | 0.04 | 0.69 (0.57–0.84) | <0.001 |
| P for trend | 0.046 | <0.001 | 0.03 |

OR: odds ratio, CI: confidence interval. Q1–Q4 indicate four groups according to the quartile of hsCRP values (mg/L). Model 1 included age, sex, baseline National Institutes of Health Stroke Scale score, and stroke subtypes. Model 2 included the same variables as those in model 1, and hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections.

doi:10.1371/journal.pone.0156790.t002
For sensitivity analyses, we analyzed the associations in patients who did not experience acute infections after stroke onset (Table 5). However, the associations between plasma hsCRP levels and clinical outcomes were still observed. Plasma hsCRP levels were not associated with early recurrence in this study (S1 Table). However, to exclude the possibility that the association was affected by early stroke recurrence or mortality, we performed additional analysis after excluding 220 patients who experienced recurrent stroke and 129 patients who died at 3 months after the onset. However, the trend was essentially unchanged (S2 Table).

### Table 3. Plasma hsCRP levels and neurological deterioration during hospitalization.

|        | Age- and sex-adjusted | Multivariable-adjusted (model 1) | Multivariable-adjusted (model 2) |
|--------|-----------------------|----------------------------------|----------------------------------|
|        | Events (%) OR (95% CI) P | OR (95% CI) P | OR (95% CI) P |
| Q1, n = 910 (hsCRP ≤0.50) | 82 (9.0) 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2, n = 936 (0.50< hsCRP ≤1.25) | 101 (10.8) 1.21 (0.89–1.64) 0.23 | 1.08 (0.79–1.49) 0.62 | 1.20 (0.88–1.66) 0.25 |
| Q3, n = 898 (1.25< hsCRP ≤4.70) | 130 (14.5) 1.64 (1.22–2.21) 0.001 | 1.47 (1.08–2.00) 0.01 | 1.57 (1.15–2.14) 0.004 |
| Q4, n = 909 (hsCRP >4.70) | 171 (18.8) 2.14 (1.61–2.85) <0.001 | 1.94 (1.43–2.62) <0.001 | 1.72 (1.26–2.34) 0.001 |
| P for trend | <0.001 | <0.001 | <0.001 |

OR: odds ratio, CI: confidence interval. Q1–Q4 indicate four groups according to the quartile of hsCRP values (mg/L). Model 1 included age, sex, baseline National Institutes of Health Stroke Scale score, and stroke subtypes. Model 2 included the same variables as those in model 1, and hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections.

doi:10.1371/journal.pone.0156790.t003

For sensitivity analyses, we analyzed the associations in patients who did not experience acute infections after stroke onset (Table 5). However, the associations between plasma hsCRP levels and clinical outcomes were still observed. Plasma hsCRP levels were not associated with early recurrence in this study (S1 Table). However, to exclude the possibility that the association was affected by early stroke recurrence or mortality, we performed additional analysis after excluding 220 patients who experienced recurrent stroke and 129 patients who died at 3 months after the onset. However, the trend was essentially unchanged (S2 Table).

### Table 4. Plasma hsCRP levels and poor functional outcome at discharge and at 3 months.

|        | Age- and sex-adjusted | Multivariable-adjusted (model 1) | Multivariable-adjusted (model 2) |
|--------|-----------------------|----------------------------------|----------------------------------|
|        | Events (%) OR (95% CI) P | OR (95% CI) P | OR (95% CI) P |
| At discharge | | | |
| Q1, n = 910 (hsCRP ≤0.50) | 191 (21.0) 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2, n = 936 (0.50< hsCRP ≤1.25) | 245 (26.2) 1.33 (1.06–1.66) 0.01 | 1.28 (0.99–1.65) 0.06 | 1.33 (1.02–1.73) 0.04 |
| Q3, n = 898 (1.25< hsCRP ≤4.70) | 331 (36.9) 2.12 (1.71–2.63) <0.001 | 1.74 (1.35–2.25) <0.001 | 1.72 (1.33–2.24) <0.001 |
| Q4, n = 909 (hsCRP >4.70) | 493 (54.2) 4.05 (3.27–5.01) <0.001 | 2.85 (2.21–3.67) <0.001 | 2.35 (1.81–3.06) <0.001 |
| P for trend | <0.001 | <0.001 | <0.001 |
| At 3 months | | | |
| Q1, n = 896 (hsCRP ≤0.50) | 166 (18.5) 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2, n = 928 (0.50< hsCRP ≤1.25) | 198 (21.3) 1.18 (0.93–1.50) 0.17 | 1.08 (0.82–1.41) 0.60 | 1.09 (0.83–1.45) 0.53 |
| Q3, n = 885 (1.25< hsCRP ≤4.70) | 282 (31.9) 1.98 (1.58–2.49) <0.001 | 1.52 (1.17–1.99) 0.002 | 1.56 (1.19–2.06) 0.001 |
| Q4, n = 894 (hsCRP >4.70) | 439 (49.1) 3.79 (3.03–4.74) <0.001 | 2.47 (1.90–3.21) <0.001 | 2.03 (1.55–2.67) <0.001 |
| P for trend | <0.001 | <0.001 | <0.001 |

OR: odds ratio, CI: confidence interval. Q1–Q4 indicate four groups according to the quartile of hsCRP values (mg/L). Model 1 included age, sex, baseline National Institutes of Health Stroke Scale score, and stroke subtypes. Model 2 included the same variables as those in model 1, and hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections.

doi:10.1371/journal.pone.0156790.t004
Subgroup analysis

The association between plasma hsCRP levels and poor functional outcome at 3 months was then investigated according to baseline characteristics (Fig 1). The trends were maintained irrespective of stroke subtype and initial neurological severity; however, odds ratios for poor functional outcome increased more markedly as an elevation of plasma hsCRP levels in patients aged < 70 years than in those aged ≥ 70 years (P for heterogeneity = 0.001). The heterogeneity between the two age groups was still found even after excluding patients with acute infections during hospitalization (P for heterogeneity = 0.003, S2 Fig). There was no heterogeneity between the two groups for stroke subtype and stroke severity.

Discussion

The present study showed that elevated plasma hsCRP levels within 24 h of onset were associated with poor short-term clinical outcomes, including neurological deterioration and poor functional outcome, in patients with acute ischemic stroke. Our findings indicate that plasma CRP was independently associated with unfavorable clinical outcomes after acute ischemic stroke.

The association between CRP in the blood and post-stroke clinical outcomes is still unclear. Although some groups showed a positive association [20-22], the number of the patients was limited, and the influence of confounding factors was not controlled. In fact, other studies reported that the association of CRP with clinical outcomes (3-month mortality [23], new vascular events [16], or stroke recurrence or death within 90 days [24]) disappeared after adjusting for confounders. In our study, however, the association was unaffected by further adjustment for potentially confounding factors, including age, vascular risk factors, stroke subtype, baseline severity, and acute infections during hospitalization. Additionally, the trends were unchanged even after excluding patients with infectious diseases occurring during hospitalization or those who experienced recurrent stroke or died within 3 months after stroke onset. Further, plasma hsCRP had a more significant impact on clinical outcomes in younger than older patients.

Plasma hsCRP levels increase with age, and post-stroke functional outcome is generally poor in aged patients. Therefore, the association may be weakened by these factors in older patients.
These findings are consistent with the concept that plasma hsCRP is a factor related to unfavorable outcomes independent of conventional risk factors and acute infections in patients with acute ischemic stroke.

CRP belongs to the pentraxin family of calcium-dependent ligand-binding plasma proteins. Human CRP is predominantly produced in hepatocytes in response to proinflammatory cytokines such as interleukin-6, and binds phosphocholine residues in a variety of autologous ligands, which is considered to be related to innate immunity in humans [1,33–35]. Although the precise mechanisms underlying the association between plasma hsCRP and clinical outcomes after ischemic stroke are unclear, there are two possible explanations. The first involves exacerbation of brain infarction, as CRP itself may worsen clinical outcomes after ischemic stroke. However, it remains unclear whether inhibition of the protein can ameliorate clinical
outcomes in acute ischemic stroke patients. Alternatively, assuming that CRP plays a beneficial rather than detrimental role via clearance of apoptotic and necrotic cells \[1,35\], plasma CRP may be elevated to counteract an exacerbating factor. Indeed, a recent study in which pure natural human CRP was administered to healthy adult human volunteers reported no proinflammatory effects \[36\]. Moreover, atherosclerosis was not reduced in CRP-deficient mice, providing evidence against a proatherogenic role of CRP \[37\]. Further studies are required to elucidate the pathophysiological role of plasma CRP in acute ischemic stroke.

The number of patients in our study was very large, enabling stratified analysis and adjustment for potential confounders. Further, even low levels of plasma CRP could be measured by high-sensitivity assays using a standardized method. However, a limitation of our study was that the exact timing of collecting the blood samples was unknown, even if it were collected within 24 h. Thus, the time elapsed from stroke onset could not be adjusted for. Nevertheless, patients with severe stroke are likely to be hospitalized early, when CRP levels are still on the rise. Therefore, this may weaken the association. Our results may also be biased by unidentified confounders that were not adjusted for. Further, although we found no sex difference in clinical outcomes (P for heterogeneity >0.07) in this study, the proportion of female individuals was small. Our findings were only in patients included in the restricted region, and cannot be generalized to the larger population. Thus, associations between plasma CRP and short-term clinical outcomes after ischemic stroke should be further validated in other cohorts.

Supporting Information

S1 Fig. Flow chart of patient selection. Selection of patients for each analysis is shown. FSR: Fukuoka Stroke Registry, ADL: activities of daily living.

S2 Fig. Subgroup analysis in patients without post-stroke acute infections. Multivariable-adjusted odds ratio and 95% confidence interval of each hsCRP quartile for poor functional outcome at 3 months in patients without acute infections during hospitalization are shown according to subgroups. Q1–Q4 indicate the four groups according to the quartile of hsCRP values (mg/L). Subgroups include age (≥70 years or <70 years), stroke subtypes (cardioembolic [CE] or others), and stroke severity (baseline NIHSS score 0–4 or NIHSS score ≥5). Multivariable model included age, sex, baseline National Institutes of Health Stroke Scale (NIHSS) score, stroke subtypes, hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, and intravenous thrombolytic therapy and endovascular therapy. In subgroup analysis for age and stroke severity, these variables were included in the model as dichotomized values. P for heterogeneity (P_{heterogeneity}) was calculated by means of the interaction term.

S1 Table. Plasma hsCRP levels and stroke recurrence during hospitalization. OR: odds ratio, CI: confidence interval. Q1–Q4 indicate the four groups according to the quartile of hsCRP values (mg/L). Model 1 included age, sex, baseline National Institutes of Health Stroke Scale score, and stroke subtypes.

S2 Table. Plasma hsCRP levels and clinical outcomes in patients without stroke recurrence or death within 3 months. OR: odds ratio, CI: confidence interval. Q1–Q4 indicate the four groups according to the quartile of hsCRP values (mg/L). Functional outcome was assessed at 3 months after stroke onset. Multivariable model included age, sex, baseline National Institutes of Health Stroke Scale score, stroke subtypes, hypertension, dyslipidemia, diabetes mellitus,
atrial fibrillation, smoking, drinking, chronic kidney disease, body mass index, intravenous thrombolytic therapy and endovascular therapy, and acute infections.

(BOC)

Acknowledgments

We thank all study participants, FSR investigators for collecting data, and all clinical research coordinators (Hisayama Research Institute for Lifestyle Diseases) for their help in obtaining informed consent and collecting clinical data.

The participating hospitals in the Fukuoka Stroke Registry were as follows: Kyushu University Hospital, National Hospital Organization Kyushu Medical Center, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka Red Cross Hospital, St. Mary’s Hospital, Steel Memorial Yawata Hospital, Japan Labor Health, and Welfare Organization Kyushu Rosai Hospital.

The Steering Committee of the FSR included Takao Ishitsuka (Fukuoka Mirai Hospital), Shigeru Fujimoto (Jichi Medical University), Setsuro Ibayashi (Seiai Rehabilitation Hospital), Kenji Kusuda (Seiai Rehabilitation Hospital), Shuji Arakawa (Steel Memorial Yawata Hospital), Katsumi Irie (Hakujyuji Hospital), Kenichiro Fujii (Fukuoka Red Cross Hospital), Tetsuhiko Nagao (Midorino clinic), Masahiro Yasaka (National Hospital Organization Kyushu Medical Center), Yasushi Okada (National Hospital Organization Kyushu Rosai Hospital), Hiroaki Ooboshi (Fukuoka Dental Collage Medical and Dental Hospital), Tsuyoshi Omae (Imazu Red Cross Hospital), Kazunori Toyoda (National Cerebral and Cardiovascular Center), Hiroshi Nakane (National Hospital Organization Fukuoka-Higashi Medical Center), Hiroshi Sugimori (Saga-Ken Medical Centre Koseikan), Kenji Fukuda (St. Mary’s Hospital), Jiro Kitayama (Fukuoka Red Cross Hospital), Shoji Arihiro (Japan Labor Health and Welfare Organization Kyushu Rosai Hospital), and Yoshihisa Fukushima (St. Mary’s Hospital).

Author Contributions

Conceived and designed the experiments: RM TA YW JK T. Kuwashiro T. Kitazono MK. Performed the experiments: RM TA JH YW JK T. Kuwashiro T. Kitazono MK. Analyzed the data: RM JH MK. Wrote the paper: RM TA JH YW JK T. Kitazono MK.

References

1. Di Napoli M, Elkind MS, Godoy DA, Singh P, Papa F, Popa-Wagner A. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev Cardiovasc Ther. 2011; 9: 1565–1584. doi:10.1586/erc.11.159 PMID: 22103876
2. Verma S, Yeh ET. C-reactive protein and atherothrombosis—beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol. 2003; 285: R1253–1256. PMID: 14557241
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979. PMID: 9077376
4. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003; 108: 166–170. PMID: 12821545
5. Wakugawa Y, Kyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke. 2006; 37: 27–32. PMID: 16396468
6. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297: 611–619. PMID: 17299196
7. Makita S, Nakamura M, Satoh K, Tanaka F, Onoda T, Kawamura K, et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in the general population.
population. Atherosclerosis. 2009; 204: 234–238. doi: 10.1016/j.atherosclerosis.2008.07.040 PMID: 18790479

8. Kaptego S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375: 132–140. doi: 10.1016/S0140-6736(09)61717-7 PMID: 20031199

9. Luna JM, Moon YP, Liu KM, Spitalnik S, Paik MC, Cheung K, et al. High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: the northern Manhattan study. Stroke. 2014; 45: 979–987. doi: 10.1161/STROKEAHA.113.002289 PMID: 24627113

10. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001; 32: 917–924. PMID: 11283392

11. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001; 32: 133–138. PMID: 11136928

12. Di Napoli M, Papa F, Villa Pini Stroke Data Bank I. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002; 33: 1763–1771. PMID: 12105349

13. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002; 33: 2459–2464. PMID: 12364738

14. Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Montaner J, Rovira A, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003; 34: 2463–2468. PMID: 14500938

15. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1998; 30: 981–985. PMID: 10229731

16. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006; 166: 2073–2080. PMID: 17060536

17. Montaner J, Fernandez-Cadenas I, Molina CA, Ribó M, Huertas R, Rosell A, et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke. 2006; 37: 1205–1210. PMID: 16601211

18. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab. 2004; 24: 1214–1218. PMID: 15545914

19. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440: 1217–1221. PMID: 16642000

20. Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis. 2009; 28: 545–550. doi: 10.1159/000247597 PMID: 19844093

21. Welsh P, Barber M, Langhome P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis. 2009; 27: 247–253. doi: 10.1159/000196823 PMID: 19176958

22. Song IU, Kim YD, Kim JS, Lee KS, Chung SW. Can high-sensitivity C-reactive protein and plasma homocysteine levels independently predict the prognosis of patients with functional disability after first-ever ischemic stroke? Eur Neurol. 2010; 64: 304–310. doi: 10.1159/000321415 PMID: 21051895

23. Christensen H, Boysen G. C-reactive protein and white blood cell count increases in the first 24 hours after acute stroke. Cerebrovasc Dis. 2004; 18: 214–219. PMID: 15279347

24. Cucchiara BL, Messe SR, Sensing L, MacKenzie L, Taylor RA, Pacelli J, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk stratification of patients with TIA. Stroke. 2009; 40: 2332–2336. doi: 10.1161/STROKEAHA.109.553945 PMID: 19461049

25. Kamouchi M, Matsuki T, Hata J, Kuwashiro T, Ago T, Sambongi Y, et al. Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. Stroke. 2011; 42: 2788–2794. doi: 10.1161/STROKEAHA.111.617415 PMID: 21817134

26. Kumei Y, Kamouchi M, Hata J, Ago T, Kitayama J, Nakane H, et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology. 2012; 78: 1909–1915. doi: 10.1212/WNL.0b013e318259e610 PMID: 22592359

27. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35–41. PMID: 7678184

28. Seino Y, Nonce K, Tajima T, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010; 1: 212–228. doi: 10.1111/j.2040-1124.2010.00074.x PMID: 24943435
29. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982–992. doi:10.1053/j.ajkd.2008.12.034 PMID: 19339088

30. Shinohara Y, Yamaguchi T. Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke. 2008; 3: 55–62. doi:10.1111/j.1747-4949.2008.00178.x PMID: 18705916

31. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008; 39: 2749–2755. doi: 10.1161/STROKEAHA.108.514307 PMID: 18703813

32. Toyoda K, Fujimoto S, Kamouchi M, Iida M, Okada Y. Acute blood pressure levels and neurological deterioration in different subtypes of ischemic stroke. Stroke. 2009; 40: 2585–2588. doi: 10.1161/STROKEAHA.108.543587 PMID: 19407233

33. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001; 38: 189–197. PMID: 11532280

34. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805–1812. PMID: 12813013

35. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005; 36: 1316–1329. PMID: 15879341

36. Lane T, Wassef N, Poole S, Mistry Y, Lachmann HJ, Gillmore JD, et al. Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res. 2014; 114: 672–676. doi: 10.1161/CIRCRESAHA.114.302770 PMID: 24337102

37. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem. 2011; 286: 6272–6279. doi: 10.1074/jbc.M110.161414 PMID: 21149301